Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Karolinska Development AB ( (SE:KDEV) ) just unveiled an announcement.
Karolinska Development’s portfolio company, BOOST Pharma, has secured a SEK 34 million investment from Sound Bioventures to support the clinical development of BT-101, a stem cell-based therapy for Osteogenesis imperfecta (OI). This investment, along with previous funding, will accelerate BOOST Pharma’s efforts to develop the first disease-modifying treatment for OI, potentially revolutionizing the treatment of this congenital condition in infants.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company that focuses on identifying and investing in breakthrough medical innovations in the Nordic region. The company aims to create and grow businesses that advance these innovations into commercial products, enhancing patient lives and providing returns to shareholders. With access to world-class medical innovations from institutions like the Karolinska Institutet, Karolinska Development supports companies targeting innovative treatments for life-threatening or serious debilitating diseases.
Average Trading Volume: 281,830
Current Market Cap: SEK236.1M
For detailed information about KDEV stock, go to TipRanks’ Stock Analysis page.